Intra-Cellular Therapies Long Term Debt

Intra-Cellular Therapies (ITCI) currently reports a long-term debt of $13M as of December 2024. That compares with $13M in the prior-year period — down 4.3% year over year. Use the charts on this page to explore Intra-Cellular Therapies's long-term debt history and peer comparisons.

Intra-Cellular Therapies's long-term debt decreased from $13M to $13M — a 4.3% year-over-year decrease (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intra-Cellular Therapies reported $13M in long-term debt as of December 2024. That compares with $13M in the prior-year period — down 4.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $13M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intra-Cellular Therapies, and consider following ITCI for alerts when major investors trade the stock.

Intra-Cellular Therapies is classified in the Healthcare sector. On long-term debt, it currently shows $13M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ITCI with unrelated industries.